



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 06 Mar 2023 (#10)

**Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.**

**Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)**

**To prepare an application can take *4-18 months*, depending on many factors:**

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

## Important Notices

**[NOT-OD-23-095](#) Expiration of the COVID-19 Public Health Emergency.** The purpose of this notice is to alert the extramural research community that the HHS declared public health emergency for COVID-19 will be terminated on May 11, 2023.

**[NOT-AG-23-011](#) Notice of Pre-Application Webinar for Funding Opportunities on “Determinants of Differences Among Human and Nonhuman Primate Species in Life Spans, Life Histories, and Other Aging-Related Outcomes, and Prospects for Translation”** The National Institute on Aging (NIA) will host a virtual pre-application webinar for the companion RFAs [RFA-AG-24-019](#) and [RFA-AG-24-020](#) on **Thursday, March 30, 2023, from 10:00 a.m. to 12:00 p.m. EST.** Please register for the webinar [here](#). A recording of the webinar will be posted on the [Frequently Asked Questions Page for RFAs AG-24-019 and AG-24-020](#), along with the slides, after the webinar.

**[NOT-RM-23-007](#) Notice of Pre-Application Webinar for PAR-23-035: Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed).** The NIH Common Fund will host a pre-application webinar to provide information and respond to questions from prospective applicants who plan to submit applications to [PAR-23-035](#) on March 3, 2023, from 12:00 pm – 1:00 pm Eastern Time (ET). After the webinar, webinar slides and a recording will be posted on the [Kids First website](#). To join the webinar, pre-registration is required at: <https://nih.zoomgov.com/meeting/register/vJltd-qsrT8jGpqU3mq-MLYQ-Q8ltvjNd6E>

**[NOT-TR-23-006](#) Request for Information (RFI): Advancing Clinical and Translational Science through Accelerating the Decentralization of Clinical Trials.** This RFI invites stakeholders throughout the scientific research, advocacy, clinical practice, industry, patient and lay communities, including the general public, to comment on how DCTs may be designed to be more effective, efficient and equitable to bring more interventions to all people, faster. In particular, comments are sought on ways to enable participants from 1) diverse backgrounds, that includes, but is not limited to race, ethnicity, socioeconomic status, background, gender, and mental or physical ability; and 2) those who are underserved, used in the context of Health Disparities related to population-based health. Responses to this RFI must be submitted electronically to the following link <https://rfi.grants.nih.gov/?s=63d1730a815c8d599f0af604>. Responses must be received by 11:59 p.m. (Eastern Standard Time) on May 12, 2023. Responses to this RFI are voluntary.

**[NOT-CA-23-047](#) Notice of Change to the Application Due Date and Correction of Budget Submission Requirement for RFA-CA-23-002 "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)"** Applications are due **March 30, 2023.**

**[NOT-AI-23-033](#) Notice of Intent to Publish a Funding Opportunity Announcement for Bioinformatics Resource Centers (BRCs) for Infectious Diseases (U24 Clinical Trials Not Allowed).** This Notice is to inform potential applicants of the National Institute of Allergy and Infectious Diseases' (NIAID) intent to publish a Funding Opportunity Announcement (FOA) to solicit applications for [NIAID Bioinformatics Resource Centers \(BRCs\) for Infectious Diseases](#) to provide knowledgebases and bioinformatics services to the infectious disease community. The BRC Program accommodates genomic and multi-omic data and tools for viruses, bacteria and eukaryotic pathogens, vectors, host-interactions, and microbiomes related to NIAID's mission to advance research on infectious diseases and in response to public health emergencies. This Notice is being provided to allow potential applicants additional time to develop meaningful collaborations, interdisciplinary teams, and responsive applications. NIAID anticipates making 1-2 awards with a five-year duration for each. Budgets for direct costs depend on number of proposed biological domains addressed in the application; budgets are not expected to exceed \$2,500,000 per year for one biological domain. Budgets are not expected to exceed \$4,800,000 per year for two biological domains. Application budgets need to reflect the actual needs of the proposed project.

**[NOT-OD-23-099](#) Notice of Intent to Publish a Funding Opportunity Announcement for Established Data Repositories and Knowledgebases (Clinical Trials Not Allowed).** This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

## Notices of Special Interest (NOSI)

**[NOT-AR-23-015](#) Availability of Urgent Competitive Revisions to Add or Expand Research and Administrative Supplements on Cutting Edge Pain Research in Rheumatic, Skin, and Musculoskeletal Disease.** The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving urgent competitive revision and administrative supplement applications focused on cutting-edge pain research in rheumatic, skin, and musculoskeletal diseases. Application Due Date is **6 June 2023**, by 5:00 PM local time of applicant organization. Requests may be for one year of support, or two years with strong justification. Individual requests cannot exceed the current year direct costs, up to \$350,000 in direct costs exclusive of Facilities and Administrative costs on sub-contracts. The parent award must be active when the application is submitted (e.g., within the originally reviewed and approved project period) and the proposed work must be completed within the currently approved project period for the existing parent award

**[NOT-CA-23-041](#) Administrative supplements to examine the effects of digital tools and interventions on patient-provider communication across the cancer control continuum.** The goal of this Notice of Special interest (NOSI) from the National Cancer Institute (NCI) is to encourage currently funded NCI extramural investigators to apply for administrative supplements to better understand the effects of digital health tools and interventions on patient-provider communication across the cancer control continuum, with the aim of developing an evidence base to inform future development, modification, and delivery of digital tools/interventions for effective cancer prevention and control. Only current awardees of an active NCI-funded R01, R37, R21, P01, P20, P30, P50, U01, UH3, U19, or U54 are eligible to apply. Requests for no-cost extensions on the parent grant to accommodate a supplement will not be permitted. The budget should not exceed \$100,000 in total costs for the entire allowable 1-year project period of the application/award. The administrative supplement application budget is limited to 1 year only. Submissions must be received by April 21, 2023 at 5:00 PM local time of applicant organization for FY 2023 funding.

**[NOT-CA-23-045](#) Administrative Supplements for NCI Division of Cancer Biology Research Programs.** The Division of Cancer Biology (DCB) at the National Cancer Institute (NCI) announces the opportunity for current awardees of DCB led programs to apply for supplemental funding to support collaborative research projects. To be eligible, the parent award must be able to receive funds in FY23 and be active throughout the 1-year project period. The parent award must not be in an extension period (e.g., cost or no-cost extension). Collaborative projects must include at least one investigator not named as key personnel on the parent award who brings unique expertise that is required for the proposed project. All requests, regardless of parent award funding mechanism, must be received by 5:00 PM local time on April 20, 2023. Supplement budget requests must reflect the actual needs of the proposed one-year project and are limited to \$100,000 direct cost per project (e.g. for a collaboration between two PSRC awardees, each could request up to \$50,000 in direct cost; for a collaborative project that includes a sub-contract the parent DCB research program award could request up to \$100,000 in direct cost to support the collaboration).

[NOT-HD-23-005](#) **Administrative Supplements to Leverage Network Infrastructure to Advance Multisite Research for Women, Children, Pregnant and Lactating Individuals and/or Persons with Disabilities.** These administrative supplement requests to existing NICHD-supported Network grants will be intended to leverage participating NICHD Networks (listed below) to address **emerging health care crises** and/or other **time-sensitive opportunities and/or issues**. All other proposals should be submitted via funding opportunity announcement [PAR-23-037](#). Requests may be for one year of support only; however, the NICHD is willing to consider exceptions on a case-by-case basis. The proposed project period of the supplement cannot extend beyond that of the parent award. A rigorous pre-application process similar to that utilized for PAR-23-037 will apply to this funding opportunity as well, but with an expedited timeline to the greatest extent possible. Applications without that prior pre-application process approval will not be accepted in response to this Notice. It is anticipated that additional NICHD Networks will eventually be added to this initiative.

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Funding Opportunity Announcements (FOA)

### 1. Genomic Community Resources (U24 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-124](#)

**Type:** U24

**Application Due Date:** May 25, 2023 through to January 25, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** To facilitate genomic research and the dissemination of its products, NHGRI supports both new and existing genomic resources of demonstrated broad value to the research community. Awards under this FOA will support the development and distribution of high-value genomic resources valuable for both basic and clinical genomics research.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application

### 2. Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-130](#)

**Type:** R01

**Application Due Date:** June 05, 2023 through to February 05, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application

### 3. Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-131](#)

**Type:** R21

**Application Due Date:** June 16, 2023 through to February 16, 2026 Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year.

#### 4. Exploratory Grants for Climate Change and Health Research Center Development (P20 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-ES-23-007](#)

**Type:** P20

**Application Due Date:** May 01, 2023 ; November 07, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to solicit P20 planning grant applications for Climate Change and Health Research Centers (CCHRCs). This program will support the development of a transdisciplinary research environment to sustain a program of fundamental and applied research to examine the impacts of climate change on health and to develop action-oriented solutions to protect the health of individuals, communities, and nations from the hazards posed by climate change. This opportunity will allow development of new research teams collaborating with communities and other partners to develop projects that generate data that will build or expand research capacity across a range of thematic scientific areas in support of the four core elements of the NIH's Initiative in climate health research: health effects research, health equity, intervention research, and training and capacity building (<https://www.nih.gov/sites/default/files/research-training/initiatives/climate-change/nih-climate-change-framework.pdf>).

**Budget:** NIH intends to commit \$30 million in FY2023 and FY2024 to fund up to 17 awards. Application budgets are limited to \$850,000 direct costs per year and need to reflect the actual needs of the proposed project. The maximum project period is 3 years.

#### 5. Using Secondary Data Analysis to Determine Whether Preventive Interventions Implemented Earlier in Life Reduce Suicide Risk (U01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-23-275](#)

**Type:** U01

**Application Due Date:** October 10, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that will integrate and harmonize existing large prevention trial data sets. The data sets should consist of well-characterized participant-level data for interventions implemented earlier in life to examine whether they reduce risk for later suicide, including suicidal thoughts and behaviors — fatal and nonfatal (STB), and related external injuries (e.g., nonfatal SUD/ODU/accidents, and all-cause mortality (e.g., National Death Index)). This U01 will be competed and funded to 1) obtain existing prevention trial data sets, with collaboration of the PD/Pis who have rights to the original data sets; 2) anonymize, aggregate, and harmonize prevention trial data sets; 3) utilize advanced computational/analytic strategies to examine whether intervening early reduces the risk for suicidal thoughts and behaviors (STB), mortality, and using theory-based approaches, examine potential mediators and moderators of outcome trajectories; and 4) oversee the preparation of a final harmonized prevention trial data set using [NIMH Data Archive \(NDA\) data dictionaries](#) and submitting other associated documentation from the various studies that will aid investigators in making use of the data coming from multiple sources that will be deposited into [NDA](#).

**Budget:** NIMH intends to commit \$3 million in FY 2024 to fund up to 1 award. Application budgets should reflect the actual needs of the proposed project in terms of the number and size of the trials that will be integrated, the anticipated data harmonization, and integration demands. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

Research Development and Support Division (RDSD) &  
Grants Management Office (GMO)  
Faculty of Medicine and Health Sciences  
K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krottoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105